Who is sponsoring NCT04418453?

NCT04418453 is sponsored by University of California, Los Angeles.

What drugs are being tested in NCT04418453?

Interventions in NCT04418453: Integration of telemedicine for MOUD in primary care.

What condition does NCT04418453 study?

NCT04418453 studies Opioid-use Disorder.

Is NCT04418453 still recruiting?

NCT04418453 is currently completed. Last updated 11 May 2023.

Last reviewed 2023-05-11 · How we verify

NCT04418453: Feasibility

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rural MOUD Telemedicine in Primary Care Phase 1

Completed Last updated 11 May 2023

What this trial tests

trial testing Integration of telemedicine for MOUD in primary care in Opioid-use Disorder in 36,762 participants. Completed in 5 November 2021.

Timeline

1 June 2020

Primary endpoint
29 July 2021

5 November 2021

Quick facts

Lead sponsor	University of California, Los Angeles
Status	Completed
Study type	OBSERVATIONAL
Enrollment	36,762
Start date	1 June 2020
Primary completion	29 July 2021
Estimated completion	5 November 2021
Sites	7 locations across United States

Drugs / interventions tested

Integration of telemedicine for MOUD in primary care

Conditions studied

Opioid-use Disorder — all drugs for Opioid-use Disorder →

Sponsor

University of California, Los Angeles

Who can join

Adults 18 to 80, any sex, with Opioid-use Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The feasibility study (Phase 1) will examine the implementation of telemedicine (TM) in six rural clinics in two states/regions with varying levels of OBOT capacity.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Identifying patients with opioid use disorder using International Classification of Diseases (ICD) codes: Challenges and opportunities.
Osterhage KP, Hser YI, Mooney LJ, Sherman S, et al · · 2024 · cited 19× · PMID 37715369 · DOI 10.1111/add.16338
Care coordination between rural primary care and telemedicine to expand medication treatment for opioid use disorder: Results from a single-arm, multisite feasibility study.
Hser YI, Mooney LJ, Baldwin LM, Ober A, et al · · 2023 · cited 12× · PMID 37074350 · DOI 10.1111/jrh.12760
Social Determinants of Health and Continuity of Medications for Opioid Use Disorder Among Patients Receiving Treatment in Rural Primary Care Settings.
Pham H, Ober A, Baldwin LM, Mooney LJ, et al · · 2024 · cited 5× · PMID 38315721 · DOI 10.1097/adm.0000000000001274
Medication treatment for opioid use disorder among rural primary care patients.
Hser YI, Zhu Y, Baldwin LM, Mooney LJ, et al · · 2024 · cited 4× · PMID 37495899 · DOI 10.1111/jrh.12785
Impact of COVID-19 on MOUD retention in a sample of rural primary care patients: A secondary analysis of electronic health records.
Calhoun S, Guo H, Fei Z, Lin C, et al · · 2024 · cited 2× · PMID 39286538 · DOI 10.1016/j.dadr.2024.100276
Medication-based treatment among rural, primary care patients diagnosed with opioid use disorder and alcohol use disorder.
Kan E, Baldwin LM, Mooney LJ, Saxon AJ, et al · · 2024 · cited 2× · PMID 38513976 · DOI 10.1016/j.josat.2024.209339
Co-occurring substance use disorders among patients with opioid use disorder in rural primary care clinics.
Zhu Y, Baldwin LM, Mooney LJ, Saxon AJ, et al · · 2024 · cited 2× · PMID 38097045 · DOI 10.1016/j.josat.2023.209269
Medications for Opioid Use Disorder Among Transition Age Youth Compared to Adults 26 or Older in Rural Settings.
Flores JM, Kan E, Mooney LJ, Pham H, et al · · 2024 · cited 1× · PMID 39697397 · DOI 10.1016/j.jaacop.2024.02.001

Verify or expand the search:

Other recruiting trials for Opioid-use Disorder

Currently open trials in the same condition.

NCT04783558 — Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk · NA · active not recruiting
NCT05011266 — Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder · Phase 2, PHASE3 · recruiting
NCT05039554 — Randomized Trial of ACT and a Care Management App in Primary Care-based Buprenorphine Treatment · NA · recruiting
NCT05033028 — Smartphones for Opiate Addiction Recovery · Phase 3 · recruiting
NCT04738825 — Promoting HIV Risk Reduction Among People Who Inject Drugs: A Stepped Care Approach Using Contingency Management With Pr · NA · recruiting

Other University of California, Los Angeles trials

Trials by the same sponsor.

NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04418453 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
Last refreshed: 11 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04418453.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing